ORPHA:157791
Epithelioid hemangioendothelioma
Also known as: EHE
Publications
7,439
Trials
9
Interventional, condition-specific
Researchers
1,026
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare vascular tumor characterized by a wide clinical variability ranging from indolent to locally aggressive behavior with a high metastatic potential. The tumor may arise anywhere in the body, most commonly in the lungs, liver and bones. Histologically, it is composed of epithelioid endothelial cells arranged in short cords and nests in a myxohyaline stroma, and molecularly, it is characterized by WWTR1-CAMTA1 (approximately 90%) or YAP1-TFE3 (approximately 10%) gene fusions. Rarely, other fusion genes are found.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015523
- MeSH:D018323
- UMLS:C0334538
- NCIT:C3800
Additional Mondo synonyms (4)
epithelioid angioendothelioma · epithelioid angiosarcoma · epithelioid hemangioendothelioma · malignant epithelioid hemangioendothelioma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7,439 matched papers (4,202 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
9 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7,439
7,439 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7,439 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
4,202 in the last 10 years · low confidence
Phrase hits: 7,438 · MeSH hits: 8
Who's working on it?
1,026
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang J5 papers · 2026
Department of Radiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Road, Jiangyang District, Luzhou, 646000, Sichuan, China.
Papers in Europe PMC - 02Chen Y4 papers · 2026
Department of Ultrasound, Zhongshan Hospital, Fudan University, Xuhui District, Shanghai, China.
Papers in Europe PMC - 03Wang H4 papers · 2026
Department of Ultrasound, Zhongshan Hospital, Fudan University, 180th Fengling Rd, Xuhui District, Shanghai, 200032, China.
Papers in Europe PMC - 04Wang Y4 papers · 2026
Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive Diseases, Shijiazhuang, Hebei Province, China.
Papers in Europe PMC - 05Xu Y4 papers · 2026
Department of Ultrasound, Zhongshan Hospital, Fudan University, 180th Fengling Rd, Xuhui District, Shanghai, 200032, China.
Papers in Europe PMC - 06Ye L4 papers · 2026
Department of Radiology, The Second People's Hospital of Quzhou, Quzhou, China.
Papers in Europe PMC - 07Li X3 papers · 2026
Department of Interventional Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Papers in Europe PMC - 08Michal M3 papers · 2025
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Prague.
Papers in Europe PMC - 09Sun J3 papers · 2026
Department of Andrology, No.2 People's Hospital of Fuyang, No. 1088, Yinghe West Road, Yingquan District, Fuyang, Anhui, China.
Papers in Europe PMC - 10Sun Y3 papers · 2026
Department of Ophthalmology, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 4 currently recruiting in our sample. 15 trials are registered for hemangioendothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
9 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.2th percentile).
low confidence · 91.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07104331·RECRUITING·SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Conditions: Epithelioid Hemangioendothelioma (EHE)·Matched via name phrase
- NCT07684287·NOT YET RECRUITING·A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Conditions: Epithelioid Hemangioendothelioma·Matched via name phrase
- NCT06452160·RECRUITING·A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Conditions: Mesothelioma · Epithelioid Hemangioendothelioma(EHE) · Solid Tumor·Matched via name phrase
- NCT03967834·RECRUITING·Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Conditions: Soft Tissue Sarcoma · Clear Cell Sarcoma · Epithelioid Sarcoma · Perivascular Epithelioid Cell Neoplasms·Matched via name phrase
Broader category: hemangioendothelioma
15
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07477548·NOT YET RECRUITING·A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Conditions: Vascular Malformations · Arteriovenous Malformations · Venous Malformation · Lymphangioma·Matched via name phrase
- NCT07131644·NOT YET RECRUITING·Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Conditions: Kaposiform Hemangioendothelioma·Matched via name phrase
- NCT07656909·RECRUITING·Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Conditions: Kaposiform Hemangioendothelioma (KHE) · Kasabach Merritt Phenomenon·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06541652·RECRUITING·A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Conditions: Hepatocholangiocarcinoma · Fibrolamellar Carcinoma · Hepatic Epithelioid Hemangioendothelioma · Hepatoblastoma·Matched via name phrase
- NCT06408441·RECRUITING·The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Conditions: Epithelioid Hemangioendothelioma · Sarcoma,Soft Tissue·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Epithelioid hemangioendothelioma" OR "epithelioid angioendothelioma" OR "epithelioid angiosarcoma" OR "malignant epithelioid hemangioendothelioma"
MeSH descriptor terms unioned into the query: Hemangioendothelioma, Epithelioid
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Epithelioid hemangioendothelioma" OR "epithelioid angioendothelioma" OR "epithelioid angiosarcoma" OR "malignant epithelioid hemangioendothelioma" OR "Hemangioendothelioma, Epithelioid"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemangioendothelioma"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: EHE
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (7439) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T07:59:07.925Z
